The transition-metal-catalyst-free oxidative homocoupling of organomanganese reagents prepared by the insertion of magnesium into organic halides in the presence of MnCl2·2LiCl
Photo–nickel dual catalytic benzoylation of aryl bromides
作者:Tobias Emanuel Schirmer、Alexander Wimmer、Florian Wolfgang Clemens Weinzierl、Burkhard König
DOI:10.1039/c9cc04726c
日期:——
The dual catalytic arylation of aromatic aldehydes by aryl bromides using UV-irradiation and a nickel catalyst is reported. The reaction product serves as a photocatalyst and a hydrogen atom transfer agent for this transformation.
Transition‐Metal‐Free Carbonylative Suzuki‐Miyaura Reactions of Aryl Iodides with Arylboronic Acids Using
<i>N</i>
‐Formylsaccharin as CO Surrogate
作者:Dezhong Yu、Fangning Xu、Dan Li、Wei Han
DOI:10.1002/adsc.201900306
日期:2019.7.2
Unprecedented, high yielding, transition‐metal‐free carbonylative Suzuki‐Miyaura reactions of aryl iodides with arylboronic acids using N‐formylsaccharin as CO surrogate have been developed. Notably, this general protocol was adapted to the synthesis of the triglyceride and cholesterol regulator drug, fenofibrate, and carbon‐13 labeled biaryl ketone.
In particular, the present invention is concerned with compounds of the general formula (I)
wherein X, Y and R
1
to R
10
are as described herein. The compounds are V1a receptor antagonists. The invention also relates to the manufacture of compounds of formula I, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases.
[EN] INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS<br/>[FR] DÉRIVÉS D'INDAZOLE À UTILISER EN TANT QU'AGONISTES INVERSES DE CB-1
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2017034872A1
公开(公告)日:2017-03-02
The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
Short synthesis of 4-chloro-4′-(chlorodifluoromethoxy)benzophenone
作者:Friedrich Karrer、Hans Meier、Alfons Pascual
DOI:10.1016/s0022-1139(99)00259-6
日期:2000.4
A one-pot, highly selective synthesis of 4-chloro-4′-(chlorodifluoromethoxy)benzophenone suitable for an industrial scale-up was developed. Fluorination of 4-(trichloromethoxy)benzoylchloride at –20°C with HF to 4-(chlorodifluoromethoxy)benzoyl fluoride followed by an in situ Friedel–Craftsreaction with chlorobenzene in the presence of BF3 at –5°C yielded the title compound in excellent yield.